$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter

Brokerages expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to announce $1.37 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Adamas Pharmaceuticals’ earnings, with estimates ranging from $1.25 million to $1.50 million. The firm is expected to issue its next quarterly earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year sales of $1.37 million for the current financial year, with estimates ranging from $21.70 million to $26.65 million. For the next financial year, analysts forecast that the business will report sales of $82.39 million per share, with estimates ranging from $75.00 million to $89.78 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Adamas Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.84 million. During the same period last year, the company earned ($0.68) earnings per share. The company’s revenue for the quarter was up 1435.1% compared to the same quarter last year.

Several equities research analysts have recently weighed in on ADMS shares. Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, February 23rd. Cowen set a $55.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 13th. Zacks Investment Research raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Wednesday, January 3rd. Piper Jaffray Companies set a $52.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Finally, BidaskClub raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $45.14.

In related news, insider Rajiv Patni sold 1,252 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the completion of the transaction, the insider now directly owns 21,515 shares of the company’s stock, valued at $558,099.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Gregory T. Went sold 4,541 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total value of $116,930.75. Following the completion of the transaction, the chief executive officer now directly owns 182,610 shares of the company’s stock, valued at $4,702,207.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,360 shares of company stock valued at $164,138. 29.00% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Alps Advisors Inc. lifted its position in Adamas Pharmaceuticals by 9.9% in the third quarter. Alps Advisors Inc. now owns 22,172 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 1,990 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Adamas Pharmaceuticals by 11.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock worth $1,041,000 after acquiring an additional 3,218 shares in the last quarter. EAM Investors LLC raised its stake in Adamas Pharmaceuticals by 5.7% during the fourth quarter. EAM Investors LLC now owns 89,585 shares of the specialty pharmaceutical company’s stock worth $3,036,000 after acquiring an additional 4,792 shares in the last quarter. SG Americas Securities LLC acquired a new position in Adamas Pharmaceuticals during the third quarter worth $110,000. Finally, Quantbot Technologies LP acquired a new position in Adamas Pharmaceuticals during the third quarter worth $119,000. 77.25% of the stock is owned by hedge funds and other institutional investors.

Adamas Pharmaceuticals stock traded down $0.64 on Friday, hitting $23.82. The stock had a trading volume of 570,452 shares, compared to its average volume of 1,094,362. Adamas Pharmaceuticals has a 12 month low of $13.50 and a 12 month high of $44.00. The company has a quick ratio of 10.69, a current ratio of 10.79 and a debt-to-equity ratio of 1.55. The company has a market capitalization of $691.63, a PE ratio of -6.02 and a beta of 1.59.

COPYRIGHT VIOLATION NOTICE: “$1.37 Million in Sales Expected for Adamas Pharmaceuticals Inc (ADMS) This Quarter” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3294342/1-37-million-in-sales-expected-for-adamas-pharmaceuticals-inc-adms-this-quarter.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

LeMaitre Vascular  Issues Q2 Earnings Guidance
LeMaitre Vascular Issues Q2 Earnings Guidance
PRCoin  Market Capitalization Hits $18,688.00
PRCoin Market Capitalization Hits $18,688.00
Creatio  Trading 7.1% Higher  This Week
Creatio Trading 7.1% Higher This Week
Cherokee  versus J.Jill  Financial Analysis
Cherokee versus J.Jill Financial Analysis
Head to Head Comparison: Allegheny Technologies  & Synalloy
Head to Head Comparison: Allegheny Technologies & Synalloy
$49.78 Million in Sales Expected for FranklinCovey  This Quarter
$49.78 Million in Sales Expected for FranklinCovey This Quarter


© 2006-2018 Ticker Report. Google+.